HomeCompareEPZM vs CL

EPZM vs CL: Dividend Comparison 2026

EPZM yields 136.05% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPZM wins by $15.35M in total portfolio value
10 years
EPZM
EPZM
● Live price
136.05%
Share price
$1.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.39M
Annual income
$6,293,323.05
Full EPZM calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — EPZM vs CL

📍 EPZM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPZMCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPZM + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPZM pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPZM
Annual income on $10K today (after 15% tax)
$11,564.63/yr
After 10yr DRIP, annual income (after tax)
$5,349,324.59/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, EPZM beats the other by $5,344,732.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPZM + CL for your $10,000?

EPZM: 50%CL: 50%
100% CL50/50100% EPZM
Portfolio after 10yr
$7.72M
Annual income
$3,149,362.51/yr
Blended yield
40.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

EPZM
Analyst Ratings
10
Buy
5
Hold
1
Sell
Consensus: Buy
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPZM buys
0
CL buys
0
No recent congressional trades found for EPZM or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPZMCL
Forward yield136.05%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$15.39M$40.8K
Annual income after 10y$6,293,323.05$5,401.96
Total dividends collected$14.14M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: EPZM vs CL ($10,000, DRIP)

YearEPZM PortfolioEPZM Income/yrCL PortfolioCL Income/yrGap
1← crossover$24,305$13,605.44$11,012$312.01+$13.3KEPZM
2$56,912$30,905.26$12,196$412.95+$44.7KEPZM
3$128,528$67,631.59$13,599$549.66+$114.9KEPZM
4$280,268$142,743.86$15,288$736.64+$265.0KEPZM
5$590,792$290,905.24$17,353$995.28+$573.4KEPZM
6$1,205,245$573,097.64$19,926$1,357.80+$1.19MEPZM
7$2,382,274$1,092,661.12$23,194$1,873.82+$2.36MEPZM
8$4,567,482$2,018,449.47$27,439$2,621.52+$4.54MEPZM
9$8,503,963$3,616,756.90$33,088$3,727.38+$8.47MEPZM
10$15,392,564$6,293,323.05$40,806$5,401.96+$15.35MEPZM

EPZM vs CL: Complete Analysis 2026

EPZMStock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Full EPZM Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this EPZM vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPZM vs SCHDEPZM vs JEPIEPZM vs OEPZM vs KOEPZM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.